Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Safety Study of Pimavanserin in Neuropsychiatric Symptoms Related to Neurodegenerative Disease
2017-003536-36Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neurodegenerative disorders (NDDs) and mental disorder comparing Pimavanserin with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jun 2018; status: completed.
02
Drugs
pimavanserin
03
Conditions
Neurodegenerative disorders (NDDs)mental disorder
Beyond the preview
Go deeper on 2017-003536-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003536-36.